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ABSTRACT 
Objective: To evaluate the correlation of raised CRP levels in 
premenopausal and postmenopausal females with 
hypothyroidism and to assess the future risk of adverse 
coronary events amongst them. 
Methodology: This was a prospective,observational,cross-
sectional,analytical study,conducted in department of 
cardiology and medicine,Gandhi medical college,Hamidia 
hospital,Bhopal from October 2013 to October 2014.Patients 
having hypothyroidism were subjected to this study.Age 
matched controls were selected randomly.Purpose of this 
study was explained and informed consent was obtained. 
Results: Percentage of raised CRP levels in hypothyroid 
premenopausal females was 13.3% and in hypothyroid 
postmenopausal females was 24.4%.CRP levels were raised 
only in 3.3% of premenopausal control group and in 10% of 
postmenopausal control group. 
Conclusion: This study showed that there is strong 
association of raised CRP levels with hypothyroidism in both 
premenopausal and postmenopausal females. 
Keywords: Crp, Hypothyroidism. 
 
I. INTRODUCTION 
CRP is called as C-reactive protein, is an 
inflammatory marker, produced by hepatocytes and is an 
acute phase reactant. Despite its name it is found to be 
elevated in both acute and chronic inflammation. More 
than 30 epidemiological studies have been done so far for 
association of raised CRP levels and adverse coronary 
events, but very few studies have shown importance of 
raised CRP levels in hypothyroidism and none have 
evaluated raised CRP levels in premenopausal and 
postmenopausal females with hypothyroidism. It has been 
found that population with raised CRP levels is associated 
with high risk of adverse coronary events. Adverse 
coronary events in our study are described as acute onset  
 
of myocardial infarction, unstable/stable angina, stroke, 
transient is chemic attack, congestive heart failure. There 
is an increased evidence of raised CRP levels and its 
association with recurrent episodes of cardiovascular 
morbidity in patients with established cardiovascular 
disease and in patients without any history of 
cardiovascular disease but having other conventional risk 
factors for cardiovascular disease.[1]studies have shown 
that CRP levels were  found to be raised in postmenopausal 
females taking hormone replacement therapy,in middle 
aged males,females having high body mass index,high 
subcutaneous and visceral fat.A strong negative predictor 
was found to be high density lipoprotein for CRP.Despite 
of extensive studies on raised CRP levels and its 
association with adverse coronary events as described 
above,it lacks specificity for cardiovascular diseases but its 
role in development of atherosclerosis and plaque’s rupture 
in atherosclerosed vessels is strong and it is a systemic as 
well as local inflammatory marker in the development  of 
atherosclerosis. 
Hypothyroidism is defined as raised TSH levels 
above the reference value (0.4-5.5micro international unit 
per millilitre) with or without decrease in free T4 
levels.Patients with only raised TSH values and clinical 
symptoms of hypothyroid are considered to have 
subclinical hypothyroidism and included in our study. 
 
II. METHODOLOGY 
The study was conducted in department of cardiology 
band medicine, Gandhi medical college, Hamidia hospital, 
Bhopal from October 2013 to September 2014.It was a 
prospective- observational, cross sectional, analytical 
study on 90 premenopausal females with hypothyroidism 
and 90 postmenopausal females with hypothyroidism and 
90 premenopausal and 90 postmenopausal females of age 
matched control groups from hospital staff and opd’s, 
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without having hypothyroism and other conventional risk 
factors for cardiovascular diseases like DM2, 
Hypertension, hyperlipedemia and high body mass index 
and other systemic illnesses. Purpose of study was 
explained to study group and control group and informed 
consent was obtained. 
 
III. INCLUSION CRITERIA 
(1) Patients diagnosed with hypothyroidism based on 
reference TSH values (0.4-5.5micro international unit per 
millilitre) and symptoms of hypothyroidism, on the basis 
of history, clinical examinations and investigations. 
(2) Females are divided into 2 main groups of 
premenopausal and postmenopausal groups.Menopause is 
defined as permanent cessation of menstrual cycle for 
continuous period of 12 months due to loss of follicular 
activities of ovaries without any evidence of pathology 
leading to amenorrhea. 
 
IV. EXCLUSION CRITERIA 
(1) Age less than 30 years 
 (2) Females on oral contraceptives,hormone replacement 
therapy 
(3) Patients with history of ischemic heart disease 
(4) Patients taking steroids  
(5) Patients with other systemic medical illnesses like liver 
diseases, renal failure, connective tissue diseases, 
rheumatoid arthritis. 
Demographic determinants (age), personal habits 
(smoking, alcohol consumption, tobacco chewing), 
physical examinations and anthropometric measurements 
were recorded. 
Blood samples were taken for biochemical 
investigations, CD-ECHO, Tread mill test if no 
contraindication), ultrasonography of abdomen were 
carried out for each case and control group. 
Diagnostic criteria for hypothyroidism is taken as 
TSH values more than reference level(0.4-5.5 micro 
international unit per millilitre) and CRP levels are termed 
qualitatively  as positive or negative. 
 
V. RESULTS 
Mean age of cases in premenopausal group was 38.83 
with standard deviation of 4.856 years. Agewise 
distribution of patients showed that maximum number of 
hypothyroid premenopausal females belong to 35 to 40 
years age group. 
Premenopausa 
  High CRP % 
Normal 
CRP % Total 
Cases 12 13.3 78 86.7 90 
Controls 3 3.3 87 96.7 90 
Total 15 8.3 165 91.7 180 
 
Chi square  4.6 
p= 0.031 
 
Mean age of cases in post menopausal group was 
51.54 with standard deviation of 4.812 years. Agewise 
distribution of patients showed that maximum number of 
hypothyroid postmenopausal females belong to 45 to 55 
years of age group. 
Postmenopausal 
 
Cases n=180  
PRE/POST MENOPAUSAL AGE BMI SBP DBP TC LDL TG HDL VLDL LVEF 
   POST 
MENOPAUSAL 
( n-80) 
Mean 51.54 27.823353 126.25 80.06 201.65 82.590 149.16 38.81 26.107937 61.43 
Std. 
Deviation 
4.812 3.7531870 13.648 11.048 53.058 21.4608 44.805 5.781 7.3555619 2.740 
Minimum 39 21.2585 110 62 116 46.0 69 24 13.8000 48 
Maximum 62 34.6260 160 110 302 124.0 288 48 44.0000 66 
Range 23 13.3675 50 48 186 78.0 219 24 30.2000 18 
  High CRP % Normal CRP % Total 
Cases 22 24.4 68 75.6 90 
Controls 9 10.0 81 90.0 90 
Total 31 17.2 149 82.8 180 
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   PRE    
MENOPAUSAL 
(n-80) 
Mean 38.83 26.678161 120.45 77.13 206.00 75.808 161.62 38.58 27.850000 62.78 
Std. 
Deviation 
4.856 3.1726284 12.554 6.915 49.984 19.4160 30.492 5.660 7.4950739 3.48 
Minimum 28 18.0802 100 62 118 45.0 98 20 15.0000 48 
Maximum 48 32.8889 154 96 296 118.0 215 48 52.0000 70 
Range 20 14.8087 54 34 178 73.0 117 28 37.0000 22 
Total Mean 44.59 27.197205 123.08 78.46 204.03 78.882 155.97 38.68 27.060432 61.54 
Std. 
Deviation 
7.972 3.4823053 13.332 9.109 51.257 20.5739 38.026 5.695 7.4562552 3.01 
Minimum 28 18.0802 100 62 116 45.0 69 20 13.8000 48 
Maximum 62 34.6260 160 110 302 124.0 288 48 52.0000 70 
Range 34 16.5458 60 48 186 79.0 219 28 38.2000 22 
 
Cases n=180  
Variables AGE BMI SBP DBP TC LDL TG HDL VLDL LVEF 
Diabetic Mean 47.04 28.649800 125.60 79.81 209.32 80.264 160.96 38.19 27.317333 61.000 
± SD 7.926 2.8021854 13.942 10.199 51.423 20.2599 160.96 5.642 7.7445774 3.500 
Minimum 32 20.5457 100 62 116 45.0 69 20 13.8000 48 
Maximum 62 34.6260 160 110 302 124.0 215 48 52.0000 70 
Range 30 14.0803 60 48 186 79.0 146 28 38.2000 22 
Non 
diabetic 
Mean 41.72 25.494945 120.13 76.88 197.83 77.263 150.13 39.27 26.759375 62.000 
± SD 7.063 3.4472895 12.026 7.405 50.761 20.9791 38.468 5.747 7.1525935 3.750 
Minimum 28 18.0802 100 68 116 45.0 69 20 13.8000 48 
Maximum 55 32.8731 154 100 296 124.0 288 48 52.0000 70 
Range 27 14.7929 54 32 180 79.0 219 28 38.2000 22 
Total Mean 44.59 27.197205 123.08 78.46 204.03 78.882 155.97 38.68 27.060432 61.000 
± SD 7.972 3.4823053 13.332 9.109 51.257 20.5739 38.026 5.695 7.4562552 3.643 
Minimum 28 18.0802 100 62 116 45.0 69 20 13.8000 48 
Maximum 62 34.6260 160 110 302 124.0 288 48 52.0000 70 
Range 34 16.5458 60 48 186 79.0 219 28 38.2000 22 
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Premenopausal 
  p-0.004 
Chi square   8.2 
 
 
Postmenopausal 
 
 DM2 
present 
% NO DM % Total 
Case 42 46.7 48 53.3 90 
Controls 20 22.2 70 77.8 90 
Total 62 34.4 118 65.6 180 
 
Chi square 4.6 
P=0.032 
 
A. Results of regression analysis 
Post menopausal group 
Dyslipidemia High 
CRP 
% 
High 
CRP 
Normal 
CR 
% 
Normal 
CRP 
Total 
YES 19 36.5 33 63.5 52 
NO 3 7.9 35 92.1 38 
Total 22 24.4 68 75.6 90 
p=0.004   Significant 
 
Pre menopausal group 
Dyslipidemia High 
CRP 
% 
High 
CRP 
Normal 
CR 
% 
Normal 
CRP 
Total 
YES 11 22.4 38 77.6 49 
NO 1 2.4 40 97.6 41 
Total 12 13.3 78 86.7 90 
p=0.013   Significant 
 
Post menopausal group 
BMI High 
CRP 
% 
High 
CRP 
Normal 
CRP 
% 
Normal 
CRP 
Total 
HIGH BMI 19 38.0 31 16.7 50 
Normal BMI 3 7.5 37 76.5 40 
Total 22 24.4 68 65.1 90 
p=0.0019  Significant  
 
Pre menopausal group  
BMI 
High 
CRP 
% 
High 
CRP 
Normal 
CRP 
% 
Normal 
CRP 
Total 
HIGH BMI 11 18.6 48 16.7 59 
Normal BMI 1 3.2 30 76.5 31 
Total 12 13.3 78 65.1 90 
p=0.085 Not significant 
 
Post menopausal group 
HTN High 
CRP 
% 
High 
CRP 
Normal 
CRP 
% 
Normal 
CRP 
Total 
YES 14 35.9 25 64.1 39 
NO 8 15.7 43 84.3 51 
Total 22 24.4 68 75.6 90 
p=0.049 Significant 
 
Pre menopausal group 
HTN High 
CRP 
% High 
CRP 
Normal 
CRP 
% 
Normal 
CRP 
Total 
YES 10 24.4 31 75.6 41 
NO 2 4.1 47 95.9 49 
Total 12 13.3 78 86.7 90 
p=0.12 Significant 
 
Incidence of fatty liver and high bmi in our study 
groups: 
Pre menopausal group 
  Fatty liver present % 
Normal 
liver % Total 
Cases 14 15.6 76 84.4 90 
Controls 4 4.4 86 95.6 90 
Total 18 10.0 162 90.0 180 
Chi square 5     
p= 0.025     
 
Postmenopausal 
  
Fatty 
liver 
presen
t 
% Normal liver % Total 
Cases 27 30.0 63 70.0 90 
Controls 11 12.2 79 87.8 90 
Total 38 21.1 142 78.9 180 
Chi square 7.5    
p= 0.006   
 
  DM2 present % 
NO 
DM % Total 
Cases 33 36.7 57 63.3 90 
Controls 15 16.7 75 83.3 90 
Total 48 26.7 132 73.3 180 
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Premenopausal 
  High BMI % 
Normal 
BMI % Total 
Cases 59 65.6 31 34.4 90 
Controls 42 46.7 48 53.3 90 
Total 101 56.1 79 43.9 180 
Chi square 5.7    
p= 0.01    
 
Postmenopausal 
  High BMI % Normal BMI % Total 
Cases 50 55.6 40 44.4 90 
Controls 35 38.9 55 61.1 90 
Total 85 47.2 95 52.8 180 
Chi square 4.3     
p= 0.03     
 
VI. DISCUSSION 
Total number of hypothyroid premenopausal 
females with raise CRP levels are 12 and 13.3% .Total 
number of euthyroid females from control group with 
raised CRP levels are 3 and 3.3%. 
Total number of hypothyroid postmenopausal 
females with raised CRP are 22 and 24.4%,whereas 
euthyroid postmenopausal females from control group 
are 9 and 10%.As shown in above tables p value for 
premenopausal females with hypothyroidism is 0.031 
which is significant and in post menopausal females with 
hypothyroidism is 0.01 which is also significant. 
Postmenopausal females with hypothyroidism with 
DM 2 are 42 and 46.7% with p value 0.032and in 
premenopausal females with hypothyroidism with DM 2 
are 33 and 36.7% with p value 0.004. 
IT is significantly found that the raised CRP levels 
are present in our study group along with the DM 2.After 
regression analysis BMI ,Hypertension and dyslipidemia 
are significantly responsible in post menopausal group 
for raised  CRP levels.Many of the premenopausal group 
in early 30’s had presented with metabolic  syndrome  
along with the hypothyroidism  which is responsible   for  
the raise CRP levels  amongst  them  and  their  risk  for  
developing  adverse  coronary  events  as mentioned  
above  ,  in  future.So  this group  is particularly  important  
for  long term. 
 
VII. CONCLUSION 
Above findings have suggested that there should be 
active interventions to screen pre and postmenopausal 
females for raised CRP levels in hypothyroidism to 
prevent future risk of adverse coronary events.In 
significant number of premenopausal and 
postmenopausal females with hypothyroidism DM2 is 
present which is again an independent risk factor for both 
raised CRP levels and adverse coronary events.However 
further studies need to be conducted and follow up of 
these cases are required to look for adverse coronary 
events.Above tables have also includes body mass 
index,systolic and diastolic blood pressures,lipid profiles 
with left ventricular ejection fractions. 
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